Skip to main content
SpringerLink
Log in

Management of Hereditary Ovarian–Breast Cancer

  • Chapter
  • First Online:
Book cover Advances in Diagnosis and Management of Ovarian Cancer

  • 1370 Accesses

Abstract

In the last years, ovarian cancer research has centred particularly on disease prevention, but an increasing number of women are occurring to gynaecology and clinical genetics clinics with family history of ovarian cancer and inherited familial mutations. Over the past 15 years, there has been substantial improvement in the understanding of hereditary ovarian cancer.

This interest derived even further in light of the identification of the BRCA1 and BRCA2 genes mutations. The importance of identifying the characteristics of hereditary ovarian cancer (HOC) and to manage the women at risk suitably can greatly improve the care of the population at the highest risk. Women at risk can be recognized by pedigree analysis and may receive counselling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. The role of risk calculation programs identifies the risks and helps in decision making for clinical options and genetic testing; they give information on the risks of the disease, its mutation status and the use of genetic testing in the management of high-risk families. Further, while a large number of surrogate preliminary markers have been identified, obviously there are limited and incomplete studies on ovarian cancer genomics. Several options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgeries. Surveillance in high-risk patients for HOC is lack of safeness. At present, chemoprevention is a controversial issue because of a number of main questions remain to be addressed in developing and testing agents for ovarian cancer chemoprevention.

Prophylactic surgery has been shown to really decrease cancer risk and it has the possibility to significantly decrease ovarian cancer mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tinelli A, Malvasi A, Leo G, Vergara D, Pisanò M, Ciccarese M, et al. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev. 2010;29(2):339–50.

    CAS  PubMed  Google Scholar 

  2. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics. 2009;10(4):240–9.

    CAS  PubMed  Google Scholar 

  3. Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group. Concise handbook of familial cancer susceptibility syndromes: second edition. J Natl Cancer Inst Monogr. 2008;2008(38):1–93.

    Google Scholar 

  4. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003;21:740–53.

    PubMed  Google Scholar 

  5. Pisanò M, Mezzolla V, Galante MM, Alemanno G, Manca C, Lorusso V, et al. A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history. Fam Cancer. 2011;10(1):65–71.

    PubMed  Google Scholar 

  6. Nielsen FC, Kruse TA, Gerdes AM. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008;47(4):772–7.

    PubMed  Google Scholar 

  7. Sinilnikova OM, Mazoyer S, Bonnardel C, Lynch HT, Narod SA, Lenoir GM. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families. Fam Cancer. 2006;5:15–20.

    CAS  PubMed  Google Scholar 

  8. Brunet J, Pèrez-Segura P. Cancer screening and genetic counselling. Rev Oncol. 2004;6(3):176–83.

    Google Scholar 

  9. National Cancer Institute (NCI). http://dcp.cancer.gov/programs-resources/groups/ed/programs/plco/about. Accessed 3 Nov 2008.

  10. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005;96:520–30.

    PubMed  Google Scholar 

  11. Chiaffarino F, Parazzini F, Bosetti C, Franceschi S, Talamini R, Canzonieri V, et al. Risk factors for ovarian cancer histotypes. Eur J Cancer. 2007;43:1208–13.

    PubMed  Google Scholar 

  12. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2005;113:977–90.

    CAS  PubMed  Google Scholar 

  13. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal Maso L, et al. Family history of cancer and risk of ovarian cancer. Eur J Cancer. 2003;39:505–10.

    CAS  PubMed  Google Scholar 

  14. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev. 2001;10:125–9.

    PubMed  Google Scholar 

  15. Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome: the impact of race on uptake of genetic counseling and testing. Methods Mol Biol. 2009;471:487–500.

    PubMed  Google Scholar 

  16. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996;56:3168–72.

    CAS  PubMed  Google Scholar 

  17. Ruffner H, Verma IM. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A. 1997;94:7138–43.

    CAS  PubMed  Google Scholar 

  18. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–26.

    CAS  PubMed  Google Scholar 

  19. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science. 2003;302:639–42.

    CAS  PubMed  Google Scholar 

  20. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science. 2003;302:636–9.

    CAS  PubMed  Google Scholar 

  21. Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270–82.

    CAS  PubMed  Google Scholar 

  22. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A. 1998;95(5):2302–6.

    CAS  PubMed  Google Scholar 

  23. Fan S, Yong X, Wang C, Yuan RQ, Meng Q, Wang JA, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 2001;20(1):77–87.

    CAS  PubMed  Google Scholar 

  24. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A. 2001;98(17):9587–92.

    CAS  PubMed  Google Scholar 

  25. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A. 1996;93:13078–83.

    CAS  PubMed  Google Scholar 

  26. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804–10.

    CAS  PubMed  Google Scholar 

  27. Marmorstein LY, Ouchi T, Stuart AA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A. 1998;95(23):13869–74.

    CAS  PubMed  Google Scholar 

  28. Crotser CB, Boehmke M. Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science. J Cancer Surviv. 2009;3(1):21–42.

    PubMed  Google Scholar 

  29. Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):28–44.

    PubMed  Google Scholar 

  30. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer. 2009;124(4):919–23.

    PubMed  Google Scholar 

  31. Nelson HD, Huffman LH, Fu R, Harris EL, Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362–79.

    CAS  PubMed  Google Scholar 

  32. Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, et al. Hereditary ovarian cancer–assessing risk and prevention strategies. Obstet Gynecol Clin North Am. 2007;34(4):651–65.

    Google Scholar 

  33. Bell DA. Origin of ovarian carcinoma. Mod Pathol. 2005;18:S19–32.

    CAS  PubMed  Google Scholar 

  34. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16:241–60.

    PubMed  Google Scholar 

  35. Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, et al. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002;6(2):93–105.

    PubMed  Google Scholar 

  36. Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K. Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test. 2005;9(1):48–53.

    CAS  PubMed  Google Scholar 

  37. Vadaparampil ST, Wey JP, Kinney AY. Psychosocial aspects of genetic counseling and testing. Semin Oncol Nurs. 2004;20(3):186–95.

    PubMed  Google Scholar 

  38. Kehoe SM, Kauff ND. Screening and prevention of hereditary gynecologic cancers. Semin Oncol. 2007;34(5):406–10.

    PubMed  Google Scholar 

  39. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med. 2006;84:16–28.

    PubMed  Google Scholar 

  40. De la Hoya M, Diez O, Pérez-Segura P, Godino J, Fernández JM, Sanz J, et al. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet. 2003;40:503–10.

    PubMed  Google Scholar 

  41. Myers ER, Havrilesky LJ, Kulasingam SL, Sanders GD, Cline KE, Gray RN, et al. Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep). 2006;(145):1–100.

    Google Scholar 

  42. Low CA, Bower JE, Kwan L, Seldon J. Benefit finding in response to BRCA1/2 testing. Ann Behav Med. 2008;35(1):61–9.

    PubMed  Google Scholar 

  43. Kieran S, Loescher LJ, Lim KH. The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test. 2007;11(1):101–10.

    PubMed  Google Scholar 

  44. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85(12):1111–20.

    PubMed  Google Scholar 

  45. Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003;14(5):439–46.

    PubMed  Google Scholar 

  46. Passaperuma K, Warner E, Hill KA, Gunasekara A, Yaffe MJ. Is mammographic breast density a breast cancer risk factor in women with BRCA mutations? J Clin Oncol. 2010;28(23):3779–83.

    CAS  PubMed  Google Scholar 

  47. Nkondjock A, Ghadirian P. Epidemiology of breast cancer among BRCA mutation carriers: an overview. Cancer Lett. 2004;205(1):1–8.

    CAS  PubMed  Google Scholar 

  48. Herman LM, Clinical and Scientific Affairs Council of the AAPA. Hereditary breast and ovarian cancers. JAAPA. 2008;21(5):18–21.

    PubMed  Google Scholar 

  49. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, et al. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol. 2008;111(1):132–6.

    PubMed  Google Scholar 

  50. Armel SR, Hitchman K, Millar K, Zahavich L, Demsky R, Murphy J, Rosen B. The use of family history questionnaires: an examination of genetic risk estimates and genetic testing eligibility in the non responder population. J Genet Couns. 2011;20(4):355–64.

    PubMed  Google Scholar 

  51. Mourits MJ, de Bock GH. Managing hereditary ovarian cancer. Maturitas. 2009;64(3):172–6.

    CAS  PubMed  Google Scholar 

  52. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33.

    PubMed  Google Scholar 

  53. Bakos AD, Hutson SP, Loud JT, Peters JA, Giusti RM, Greene MH. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect. 2008;11(3):220–31.

    PubMed  Google Scholar 

  54. Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs. 2006;10(1):77–81.

    PubMed  Google Scholar 

  55. Wakahara F, Kikkawa F, Nawa A, et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest. 2001;52:147–52.

    CAS  PubMed  Google Scholar 

  56. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114(12):1500–9.

    CAS  PubMed  Google Scholar 

  57. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br J Radiol. 2008;81(963):172–9.

    PubMed  Google Scholar 

  58. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. Am J Med Genet A. 2005;133A(2):165–9.

    PubMed  Google Scholar 

  59. Lacey Jr JV, Greene MH, Buys SS, Reding D, Riley TL, Berg CD, Fagerstrom RM, Hartge P. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol. 2006;108(5):1176–84.

    PubMed  Google Scholar 

  60. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119(1):7–17.

    PubMed  Google Scholar 

  61. Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Evid Rep Technol Assess. 2006;130:1–145.

    Google Scholar 

  62. Bast Jr RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007;174:91–100.

    CAS  PubMed  Google Scholar 

  63. Geomini P, Kruiwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009;113:384–94.

    PubMed  Google Scholar 

  64. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol. 1994;170(1 Pt 1):81–5.

    CAS  PubMed  Google Scholar 

  65. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer. 2006;94(6):814–9.

    CAS  PubMed  Google Scholar 

  66. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, Van Nagell Jr JR. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003;91(1):46–50.

    CAS  PubMed  Google Scholar 

  67. Narod SA, Sun P, Risch HA. Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med. 2001;345:1706–7.

    CAS  PubMed  Google Scholar 

  68. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, National Israel Ovarian Cancer Study Group, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235–40.

    CAS  PubMed  Google Scholar 

  69. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynaecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998;90:597–605.

    CAS  PubMed  Google Scholar 

  70. Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F, Formelli F. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer. 1996;65:491–7.

    CAS  PubMed  Google Scholar 

  71. Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem. 1997;40:3567–83.

    CAS  PubMed  Google Scholar 

  72. Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT, Benbrook DM. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001;93:516–25.

    CAS  PubMed  Google Scholar 

  73. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994;23:1133–6.

    CAS  PubMed  Google Scholar 

  74. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86:40–6.

    CAS  PubMed  Google Scholar 

  75. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–67.

    CAS  PubMed  Google Scholar 

  76. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:903–6.

    CAS  PubMed  Google Scholar 

  77. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, et al. A case–control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:933–7.

    CAS  PubMed  Google Scholar 

  78. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104–7.

    CAS  PubMed  Google Scholar 

  79. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90:1529–36.

    CAS  PubMed  Google Scholar 

  80. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst. 1998;90:1609–20.

    CAS  PubMed  Google Scholar 

  81. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16.

    CAS  PubMed  Google Scholar 

  82. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci. 2000;21:469–74.

    CAS  PubMed  Google Scholar 

  83. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest. 1997;100:3149–53.

    CAS  PubMed  Google Scholar 

  84. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465–70.

    CAS  PubMed  Google Scholar 

  85. You YN, Lakhani VT, Wells Jr SA. The role of prophylactic surgery in cancer prevention. World J Surg. 2007;31(3):450–64.

    PubMed  Google Scholar 

  86. Gien LT, Mackay HJ. The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer. J Oncol. 2010;2010:151750.

    PubMed  Google Scholar 

  87. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. “BRCAness” syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530–6.

    PubMed  Google Scholar 

  88. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.

    CAS  PubMed  Google Scholar 

  89. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    CAS  PubMed  Google Scholar 

  90. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007;19(1):27–30.

    PubMed  Google Scholar 

  91. ACOG. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol. 2008;111(1):231–41.

    Google Scholar 

  92. Miller SM, Roussi P, Daly MB, Scarpato J. New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res. 2010;16(21):5094–106.

    CAS  PubMed  Google Scholar 

  93. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, National Comprehensive Cancer Network, et al. Genetic/familial high risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8:562–94.

    CAS  PubMed  Google Scholar 

  94. Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24(28):4642–60.

    PubMed  Google Scholar 

  95. Tinelli A, Malvasi A, Casciaro S, Leo G, Vergara D, Pisanò M, et al. Tailoring minimally invasive gynaecological surgery based on biogenomic findings. In: Casciaro S, Gersak B, editors. New technology frontiers in minimally invasive therapies, vol. 6. Lecce: Lupiensis Biomedical Publications; 2007. p. 43–62.

    Google Scholar 

  96. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Society of Gynecologic Oncologists Education Committee, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107(2):159–62.

    PubMed  Google Scholar 

  97. Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008;8:101.

    PubMed  Google Scholar 

  98. Gómez García EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FBL, Hoogerbrugge N, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res. 2009;11(1):R8.

    PubMed  Google Scholar 

  99. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.

    CAS  PubMed  Google Scholar 

  100. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17(3):594–604.

    PubMed  Google Scholar 

  101. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204(1):19.e1–6.

    Google Scholar 

  102. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet. 2001;357:1467–70.

    CAS  PubMed  Google Scholar 

  103. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, PLCO Project Team, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303.

    CAS  PubMed  Google Scholar 

  104. Kuliev A, Verlinsky Y. Place of preimplantation diagnosis in genetic practice. Am J Med Genet A. 2005;134A:105–10.

    PubMed  Google Scholar 

  105. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327–40.

    PubMed  Google Scholar 

  106. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, The PLCO Project Team, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775–82.

    CAS  PubMed  Google Scholar 

  107. Tinelli A, Pellegrino M, Malvasi A, Lorusso V. Laparoscopical management ovarian early sex cord-stromal tumors in postmenopausal women: a proposal method. Arch Gynecol Obstet. 2011;283 Suppl 1:87–91.

    PubMed  Google Scholar 

  108. Nezhat FR, DeNoble SM, Liu CS, Cho JE, Brown DN, Chuang L, et al. The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers. JSLS. 2010;14(2):155–68.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce, 73100, Italy

    Andrea Tinelli MD

  2. Department of Obstetrics and Gynecology, SS. Annunziata Hospital, Chieti, Italy

    Sarah Gustapane MD

  3. Department of Obstetrics and Gynecology, Santa Maria Hospital, Bari, Italy

    Antonio Malvasi MD

  4. Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy

    Daniele Vergara BSc, PhD & Michele Maffia PhD

  5. Laboratory of Medical Genetics, Giovanni Paolo II Oncological Centre, Lecce Hospital, Lecce, Italy

    Marilena Greco PhD, BSc

  6. Department of Oncology, Vito Fazzi Hospital, Lecce, 73100, Italy

    Caterina Accettura MD, Marianna Giampaglia MD & Silvana Leo MD

  7. Department of Medical Oncology, National Institute for Cancer Research, Istituto Tumori Giovanni Paolo II, Bari, Italy

    Vito Lorusso MD

Authors
  1. Andrea Tinelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Gustapane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Malvasi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniele Vergara BSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michele Maffia PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marilena Greco PhD, BSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caterina Accettura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marianna Giampaglia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Silvana Leo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vito Lorusso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Tinelli MD .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Weill Cornell Medical College, The New York Presbyterian Hospital-Weill Cornell Medical Center, Cornell University, New York, USA

    Samir A. Farghaly

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tinelli, A. et al. (2014). Management of Hereditary Ovarian–Breast Cancer. In: Farghaly, S. (eds) Advances in Diagnosis and Management of Ovarian Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-8271-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8271-0_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-8270-3

  • Online ISBN: 978-1-4614-8271-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation